Clarity Pharmaceuticals Ltd (CU6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has a cash flow conversion efficiency ratio of -0.240x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-44.75 Million ≈ $-31.67 Million USD) by net assets (AU$186.11 Million ≈ $131.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CU6 market cap for the company's overall valuation and market capitalisation.
Clarity Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2018–2026)
This chart illustrates how Clarity Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clarity Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. See CU6 operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
0.105x |
|
Caisse Regionale de Credit Agricole Mutuel Brie Picardie
PA:CRBP2
|
0.133x |
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
0.064x |
|
Atlanta Braves Holdings, Inc. Series A Common Stock
NASDAQ:BATRA
|
-0.003x |
|
G-Tech Optoelectronics Corp
TW:3149
|
-0.055x |
|
Insteel Industries Inc
NYSE:IIIN
|
-0.002x |
|
Alpha Hpa Ltd
AU:A4N
|
-0.029x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.100x |
Annual Cash Flow Conversion Efficiency for Clarity Pharmaceuticals Ltd (2018–2026)
The table below shows the annual cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2018 to 2026. View current stock price of Clarity Pharmaceuticals Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$186.11 Million ≈ $131.68 Million |
AU$-92.55 Million ≈ $-65.48 Million |
-0.497x | +18.08% |
| 2025-06-30 | AU$90.23 Million ≈ $63.84 Million |
AU$-54.77 Million ≈ $-38.75 Million |
-0.607x | -105.38% |
| 2024-06-30 | AU$146.30 Million ≈ $103.51 Million |
AU$-43.24 Million ≈ $-30.59 Million |
-0.296x | +25.66% |
| 2023-06-30 | AU$69.18 Million ≈ $48.95 Million |
AU$-27.50 Million ≈ $-19.46 Million |
-0.398x | -175.41% |
| 2022-06-30 | AU$92.24 Million ≈ $65.26 Million |
AU$-13.31 Million ≈ $-9.42 Million |
-0.144x | +61.87% |
| 2021-06-30 | AU$20.28 Million ≈ $14.35 Million |
AU$-7.68 Million ≈ $-5.43 Million |
-0.379x | +54.78% |
| 2020-06-30 | AU$8.16 Million ≈ $5.77 Million |
AU$-6.83 Million ≈ $-4.83 Million |
-0.837x | -108.35% |
| 2019-06-30 | AU$9.23 Million ≈ $6.53 Million |
AU$-3.71 Million ≈ $-2.62 Million |
-0.402x | +48.30% |
| 2018-06-30 | AU$1.93 Million ≈ $1.37 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.777x | -- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more